explore -WSS

explore

author：fashion 2025-09-06 03:54:44 - browse：15

ANDREW YATES/AFP via Getty Images

In patients with stage 3 lung cancer where a particular genetic mutation is present in the tumor, taking AstraZeneca’s cancer-fighting pill Tagrisso reduced the chance that disease would progress by 84%.

“This will be practice changing as soon as this becomes available,” said David R. Spigel, chief scientific officer of the Sarah Cannon Research Institute at a press conference announcing the results at the annual meeting of the American Society of Clinical Oncology. “This will be how patients are treated wherever they can get access to this drug.”

Spigel but was not involved in the Tagrisso study but has relationships with multiple drugmakers including AstraZeneca.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： My chronic pain journey would have been easier knowing 5 things % STAT

WSS

What Henrietta Lacks's story taught me about my role as a doctor

Lilly's Alzheimer's drug donanemab backed by FDA advisers

My daughter's legacy lives on through her writing, phage therapy

Severe heat forecast: Where scorching temperatures will persist over the next week

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

4 missing after record

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Alkermes shareholders re

How to protect coverage of PrEP

Dobbs anniversary: the lost opportunity of abortion as health care

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Jerome Adams on the need for new antivirals for Covid

Novartis develops a rapidly manufactured CAR

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Study: Why relieving medical debt did not improve financial outcomes

Hepatitis C has a cure — but many Americans still lack access to it

Medical device trials still don't enroll enough women, study finds

explore

'Essentially witchcraft:' A former naturopath takes on the field

Men with early prostate cancer can safely opt out of treatment

How a key Senate committee is planning to regulate PBMs

Statins reduce cardiovascular risk in people living with HIV

How to protect coverage of PrEP

The system is set up to fail children with medical complexity

knowledge

knowledge

entertainment

leisure time